Shares in Canada’s NervGen Pharma (TSX-V: NGEN) closed 8% lower after trading on Friday.
NervGen earlier announced that the board of directors and Paul Brennan have mutually agreed that Mr Brennan will step down as president and chief executive and a member of the board, effective immediately.
"Paul has helped position NervGen to become a leading player in the emerging central nervous system repair field"Mr Brennan had been in the role for less than three years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze